arrow
D

Donald A. Berry

berry consultants llc
H指数:109
被引数:6.0万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Update on GBM AGILE: A global, phase 2/3 adaptive platform trial to evaluate multiple regimens in newly diagnosed and recurrent glioblastoma

GBM AGILE更新:一项全球性、II/III期自适应平台试验,旨在评估新诊断和复发性胶质母细胞瘤中的多种治疗方案

2025-11-010
OAAI
Pexidartinib and standard neoadjuvant therapy in the adaptively randomized I-SPY2 trial for early breast cancer
2024-12-030
OAAI
EVALUATION OF PAXALISIB IN GBM AGILE PHASE 3 REGISTRATION PLATFORM TRIAL FOR NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA

PAXALISIB在新诊断和复发胶质母细胞瘤的GBM敏捷3期注册平台试验中的评估

2024-11-110
PRE
UPDATE ON GBM AGILE: A GLOBAL, PHASE 2/3 ADAPTIVE PLATFORM TRIAL TO EVALUATE MULTIPLE REGIMENS IN NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA

GBM AGILE的更新: 一项全球2/3期适应性平台试验,用于评估新诊断和复发性胶质母细胞瘤的多种治疗方案

2024-11-110
PRE
Multi-platform biomarkers of response to an immune checkpoint inhibitor in the neoadjuvant I-SPY 2 trial for early-stage breast cancer
2024-11-010
OAAI
A GLOBAL EXPANSION OF GBM AGILE: A PHASE 2/3 ADAPTIVE PLATFORM TRIAL TO EVALUATE MULTIPLE REGIMENS IN NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA
2024-10-170
PRE
Final results of IMPACT 2, a randomized study evaluating molecular profiling and targeted agents in metastatic cancer at MD Anderson Cancer Center

IMPACT 2研究的最终结果,这是一项在MD Anderson癌症中心进行的随机研究,旨在评估转移性癌症中的分子分型和靶向药物。

2024-09-010
PRE
Update on GBM AGILE: A global, phase II/III adaptive platform trial to evaluate multiple regimens in newly diagnosed and recurrent glioblastoma

GBM AGILE更新:一项全球性、Ⅱ/Ⅲ期适应性平台试验,用于评估新诊断和复发胶质母细胞瘤中的多种方案

2024-09-010
PRE
Collaborative Modeling to Compare Different Breast Cancer Screening Strategies

协作建模比较不同乳腺癌筛查策略

2024-06-1112
PRE
UPDATE ON GBM AGILE: A GLOBAL, PHASE 2/3 ADAPTIVE PLATFORM TRIAL TO EVALUATE MULTIPLE REGIMENS IN NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA.
2023-09-080
OA
GBM AGILE: A global, phase 2/3 adaptive platform trial to evaluate multiple regimens in newly diagnosed and recurrent glioblastoma
2023-04-140
PRE
Evaluation of anti-PD-1 Cemiplimab plus anti-LAG-3 REGN3767 in early-stage, high-risk HER2-negative breast cancer: Results from the neoadjuvant I-SPY 2 TRIAL
2023-03-015
PRE
PD11-01 Evaluation of the PD-1 Inhibitor Cemiplimab in early-stage, high-risk HER2-negative breast cancer: Results from the neoadjuvant I-SPY 2 TRIAL
2023-03-011
PRE